To determine if a hypersensitive-type lung pathology might occur when mice were given an inactivated MERS-CoV vaccine and challenged with infectious virus as was seen with SARS-CoV vaccines, we prepared and vaccinated mice with an inactivated MERS-CoV vaccine. Neutralizing antibody was induced by vaccine with and without adjuvant and lung virus was reduced in vaccinated mice after challenge. Lung mononuclear infiltrates occurred in all groups after virus challenge but with increased infiltrates that contained eosinophils and increases in the eosinophil promoting IL-5 and IL-13 cytokines only in the vaccine groups. Inactivated MERS-CoV vaccine appears to carry a hypersensitive-type lung pathology risk from MERS-CoV infection that is similar to that found with inactivated SARS-CoV vaccines from SARS-CoV infection.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5027702 | PMC |
| http://dx.doi.org/10.1080/21645515.2016.1177688 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Increased Susceptibility of Bats to Respiratory SARS-CoV-2 Challenge Despite Its Distinct Tropism for Gut Epithelia in Bats.
Viruses
October 2024
Institute of Novel and Emerging Infectious Diseases, Friedrich-Loeffler-Institut, Federal Research Institute for Animal Health, Suedufer 10, 17493 Greifswald-Insel Riems, Germany.
Article Synopsis
- Bats are considered the primary hosts for many coronaviruses, particularly Betacoronaviruses, which can cause severe respiratory diseases in humans.
- Research showed that Egyptian fruit bats were more susceptible to respiratory infections (like SARS-CoV-2) compared to oral infections, with significant differences in virus shedding and immune response.
- The study suggests that SARS-CoV-2 is likely inactivated in the bats' stomachs, making oral infections less effective, highlighting the unique pathology of coronavirus infections in bats.
Antiseptics: An expeditious third force in the prevention and management of coronavirus diseases.
Curr Res Microb Sci
October 2024
Department of Microbiology, Faculty of Biological Sciences, University of Nigeria, Nsukka 410001 Enugu State, Nigeria.
Notably, severe acute respiratory syndrome (SARS), Middle East respiratory syndrome (MERS) and coronavirus disease 2019 (COVID-19) have all had significant negative impact on global health and economy. COVID-19 alone, has resulted to millions of deaths with new cases and mortality still being reported in its various waves. The development and use of vaccines have not stopped the transmission of SARS coronavirus 2 (SARS-CoV-2), the etiological agent of COVID-19, even among vaccinated individuals.
View Article and Find Full Text PDFVirucidal activity of porphyrin-based metal-organic frameworks against highly pathogenic coronaviruses and hepatitis C virus.
Mater Today Bio
October 2024
Unité de Catalyse et Chimie du Solide (UCCS), Univ. Lille, CNRS, Centrale Lille, Univ. Artois, F-59000, Lille, France.
The antiviral effect of four porphyrin-based Metal-Organic Frameworks (PMOFs) with Al and Zr, namely Al-TCPP, PCN-222, PCN-223 and PCN-224 was assessed for the first time against HCoV-229E, two highly pathogenic coronaviruses (SARS-CoV-2 and MERS-CoV) and hepatitis C virus (HCV). Infection tests were done under dark or light exposure for different contact times, and it was found that 15 min of light exposure were enough to give antiviral properties to the materials, therefore inactivating HCoV-229E by 99.98 % and 99.
View Article and Find Full Text PDFImmunization against Medically Important Human Coronaviruses of Public Health Concern.
Can J Infect Dis Med Microbiol
June 2024
School of Medicine, The University of Jordan, Amman, Jordan.
SARS-CoV-2 is a virus that affects the human immune system. It was observed to be on the rise since the beginning of 2020 and turned into a life-threatening pandemic. Scientists have tried to develop a possible preventive and therapeutic drug against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and other related coronaviruses by assessing COVID-19-recovered persons' immunity.
View Article and Find Full Text PDFThe safety, immunogenicity, and efficacy of heterologous boosting with a SARS-CoV-2 mRNA vaccine (SYS6006) in Chinese participants aged 18 years or more: a randomized, open-label, active-controlled phase 3 trial.
Emerg Microbes Infect
December 2024
Department of Clinical Pharmacy, The First Hospital of Hebei Medical University, Shijiazhuang, People's Republic of China.
Continuous emergence of new variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), enhanced transmissibility, significant immune escape, and waning immunity call for booster vaccination. We evaluated the safety, immunogenicity, and efficacy of heterologous booster with a SARS-CoV-2 mRNA vaccine SYS6006 versus an active control vaccine in a randomized, open-label, active-controlled phase 3 trial in healthy adults aged 18 years or more who had received two or three doses of SARS-CoV-2 inactivated vaccine in China. The trial started in December 2022 and lasted for 6 months.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!